ZIRCON Phase 3 IND Submitted to the US FDA
2019-12-24 · Telix Pharmaceuticals (Innovations) Pty Limited · original telixpharma.com ↗
ZIRCON Phase 3 IND Submitted to the US FDA Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for TLX250-CDx Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3 Investigational New Drug (IND) application to the United States Food and Drug Administration for TLX250-CDx (89Zr-girentuximab, for the imaging of renal cancer with Position Emission Tomography) as part of the international Phase 3 ZIRCON study. The ZIRCON study is expected to commence enrolling US patients in Q1 2020. To read the full media release please click here.
The release as fetched from its publisher. telixpharma.com ↗